JP2014515407A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515407A5
JP2014515407A5 JP2014513785A JP2014513785A JP2014515407A5 JP 2014515407 A5 JP2014515407 A5 JP 2014515407A5 JP 2014513785 A JP2014513785 A JP 2014513785A JP 2014513785 A JP2014513785 A JP 2014513785A JP 2014515407 A5 JP2014515407 A5 JP 2014515407A5
Authority
JP
Japan
Prior art keywords
group
bonds
pharmaceutical formulation
divalent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014513785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515407A (ja
JP6448366B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/040711 external-priority patent/WO2012167236A1/en
Publication of JP2014515407A publication Critical patent/JP2014515407A/ja
Publication of JP2014515407A5 publication Critical patent/JP2014515407A5/ja
Application granted granted Critical
Publication of JP6448366B2 publication Critical patent/JP6448366B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014513785A 2011-06-03 2012-06-04 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 Active JP6448366B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492940P 2011-06-03 2011-06-03
US61/492,940 2011-06-03
PCT/US2012/040711 WO2012167236A1 (en) 2011-06-03 2012-06-04 Oral formulations of mitochondrially-targeted antioxidants and their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017196849A Division JP6461276B2 (ja) 2011-06-03 2017-10-10 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用

Publications (3)

Publication Number Publication Date
JP2014515407A JP2014515407A (ja) 2014-06-30
JP2014515407A5 true JP2014515407A5 (enExample) 2015-07-02
JP6448366B2 JP6448366B2 (ja) 2019-01-09

Family

ID=47259946

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014513785A Active JP6448366B2 (ja) 2011-06-03 2012-06-04 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用
JP2017196849A Active JP6461276B2 (ja) 2011-06-03 2017-10-10 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017196849A Active JP6461276B2 (ja) 2011-06-03 2017-10-10 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用

Country Status (10)

Country Link
US (2) US9192676B2 (enExample)
EP (1) EP2714024B1 (enExample)
JP (2) JP6448366B2 (enExample)
CN (1) CN103764132B (enExample)
AU (1) AU2012261854B2 (enExample)
BR (1) BR112013030605A2 (enExample)
CA (1) CA2837437C (enExample)
EA (1) EA031399B1 (enExample)
ES (1) ES2704064T3 (enExample)
WO (1) WO2012167236A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704064T3 (es) * 2011-06-03 2019-03-14 Mitotech Sa Formulaciones orales de antioxidantes dirigidos mitocondrialmente y su preparación y uso
WO2014116591A2 (en) * 2013-01-22 2014-07-31 Mitotech Sa Pharmaceutical formulations containing mitochondrially-targeted antioxidants
EP3030267A2 (en) * 2013-04-11 2016-06-15 Mitotech SA Mitochondrially-targeted timoquinones and toluquinones
EP3116470B1 (en) * 2014-02-25 2019-05-08 Mitotech SA Cosmetic compositions of mitochondrially targeted antioxidants
WO2019139831A1 (en) * 2018-01-10 2019-07-18 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate
EP4072512A4 (en) * 2019-12-10 2024-01-10 Mitotech S.A. POLYMER MATRICES FOR VARIOUS COMPOSITIONS OF MITOCHONDRIALLY DIRECTED ANTIOXIDANTS
JP2023520698A (ja) * 2020-04-03 2023-05-18 ミトテック ソシエテ アノニム 重度の炎症状態を処置するためのミトコンドリア標的抗酸化物質の使用
CN114344274A (zh) * 2022-01-05 2022-04-15 盖茨汉普(武汉)植物应用研究有限公司 一种Mitoq抗氧化硬胶囊配方及制备工艺
AU2024359416A1 (en) * 2023-10-11 2026-05-28 Mitotech S.A. Mitochondria-targeted antioxidants for use in the treatment of cell balloooning-associated diseases, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538974A (en) 1994-01-27 1996-07-23 Senju Pharamceutical Co., Ltd. Ophthalmic composition for lowering intraocular pressure
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
CN1318434C (zh) 1997-11-25 2007-05-30 安迪珀蒂恩生物工艺学有限公司 线粒体靶向的抗氧剂
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US20070270381A1 (en) 2000-05-25 2007-11-22 Antipodean Pharmaceuticals, Inc. Mitochondrially targeted antioxidants
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
CA2397684A1 (en) 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
AU2005261654A1 (en) 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
KR20070057218A (ko) 2004-08-30 2007-06-04 가부시키가이샤 가네카 미토콘드리아 활성화제
RU2318500C2 (ru) 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
EP2095713A1 (en) 2006-10-20 2009-09-02 Limited Liability Company "Mitotechnology" Composition for regenerating and stimulating growth of plants and for adapting plants to different stress factors
EA200900582A1 (ru) 2006-10-20 2009-08-28 Общество С Ограниченной Ответственностью "Митотехнология" Фармацевтические композиции для профилактики и лечения глазных патологий
EP2145623A4 (en) * 2007-01-29 2010-10-27 Ltd Liability Company Mitotech PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR ACCELERATING THE PROCESS OF WOUND HEALING AND OTHER SURFACE INJURIES
WO2008127138A1 (fr) * 2007-04-11 2008-10-23 Limited Liability Company 'mitotechnology' Composition visant à ralentir le vieillissement et à allonger la durée de vie de l'organisme et utilisation de cette composition
US8518915B2 (en) * 2007-06-29 2013-08-27 Mitotech Sa Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
EP2303824B1 (en) * 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EA201101576A1 (ru) 2009-04-28 2012-04-30 Эдисон Фармасьютикалз, Инк. Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
EA025414B1 (ru) * 2009-06-10 2016-12-30 Общество С Ограниченной Ответственностью "Митотех" Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
MX2012005356A (es) * 2009-11-13 2013-01-29 Obschestvo S Ogranichennoi Otvetstvennostyu Mitotekh Substancias farmaceuticas basadas en antioxidantes dirigidos a mitocondria.
ES2704064T3 (es) * 2011-06-03 2019-03-14 Mitotech Sa Formulaciones orales de antioxidantes dirigidos mitocondrialmente y su preparación y uso

Similar Documents

Publication Publication Date Title
US20220071929A1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
ES2745471T3 (es) Formulaciones orales de liberación inmediata para quinazolinonas sustituidas
JP6462045B2 (ja) スルフォラファンの単離及び精製
JP2015530382A5 (enExample)
JP2009102342A5 (enExample)
JP2020517727A5 (enExample)
JP2016534063A5 (enExample)
RU2013121788A (ru) Ингибиторы репликации вич
JP2013511496A5 (enExample)
JP2013545730A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
NZ703564A (en) Oral formulations and lipophilic salts of methylnaltrexone
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2016516772A (ja) オキサシクロヘプタン及びオキサビシクロヘプテンの配合物
JP2016516773A5 (enExample)
RU2016138795A (ru) Композиции на основе циклодекстрина и производного будесонида и способы их получения
JP5837919B2 (ja) (e)−4−カルボキシスチリル−4−クロロベンジルスルホンの改善された安定な水性製剤
CN104244936A (zh) 镇痛剂
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
RU2018130097A (ru) Лечение экземы кистей
JP2017516828A5 (enExample)
RU2012116226A (ru) Бронхолитическое средство на основе простагландина
KR20090040299A (ko) 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물
JP2014530200A5 (enExample)
JP2009538822A (ja) 静脈におけるウイルスの治療